


*Research to Practice: Hodgkin and Non-Hodgkin Lymphoma * ASH 2021, Atlanta*

MANTLE CELL LYMPHOMA


STANDARD OF CARE AND FUTURE TRENDS



Prof. Dr. Martin Dreyling
Dept. of Medicine III
LMU Hospital München


MCL: Standard of care and future trends

Prognostic risk factors



MCL : *Standard of care and future trends*


Characteristics of high risk MCL (blastoid, Ki-67 >30%, or p53mut)




	Numbers At Risk												
	years from study registration												
No HRD	132	121	111	101	91	72	61	44	33	22	12	5	0
HRD	233	183	138	108	88	70	54	39	23	16	11	5	0

Mantle cell lymphoma: *Standard of care and future trends*

Therapeutic algorithm




R-CHOP vs R-DHAP: Time to treatment failure



Numbers At Risk											
		0	1	2	3	4	5	6	7	8	9
R-DHAP	232	190	170	150	111	77	52	26	6	0	
R-CHOP	234	176	153	125	82	53	35	24	6	0	


Mantle cell lymphoma : *Standard of care and future trends*

Therapeutic algorithm



MCL : Standard of care and future trends


First line regimen VR-CAP vs R-CHOP



No. at Risk

R-CHOP	244	181	116	79	55	36	22	16	9	3	0	0
VR-CAP	243	187	146	122	94	66	42	28	17	8	1	0

Robak, NEJM 2015



No. at risk


R-CHOP	244	216	206	193	179	162	148	134	110	100	91	87	70	46	30	22	11	1	0
VcR-CAP	243	213	201	192	177	164	154	142	137	128	118	110	94	71	49	36	19	8	0

Median follow-up: approx. **80 months**

Robak, Lancet Oncol 2019

Mantle cell lymphoma: *Standard of care and future trends*

Therapeutic algorithm



MCL first line: *Standard of care and future trends*


Salvage TREATMENT

MANTLE-FIRST



LMU KLINIKUM

Early POD




At risk:

BAC	31	24	13	12	9	8	5	4	3	3	3
BR	22	16	10	7	7	6	5	5	4	3	2
ibru	27	21	16	8	5	3	0	0	0	0	0
other	47	35	24	17	17	17	15	11	11	10	6

*Ibru vs R-B and R-BAC (P=0.02); vs others (P=0.03)

Late-POD



At risk:


BAC	45	45	40	35	26	23	16	14	12	8	7
BR	32	30	26	23	22	20	16	15	13	10	9
ibru	23	22	20	18	10	6	6	4	0	0	0
other	34	31	27	24	23	19	16	13	12	8	7

Visco, Leukemia 2020

Menyang, ASH 2021, #182: Real life experience

European MCL Network


Study generation 2021





Triangle


add on vs head to head comparison



superiority/non-inferiority: time to treatment failure
HR: 0.60; 65% vs. 77% vs. 49% at 5 years

Mantle cell lymphoma (first line)

MCL elderly R2




sponsor: LYSARC

central pathology: W. Klapper

MRD diagnostics: M. Ladetto, C. Pott, MH Delfau

European MCL Network


Study generation 2021





IMCL-2015: SURVIVAL

(Data cut-off 22 Jan 2021)



MCL progression (4):
 At 12, 38, 40 and 52 mo
 † (4, 1 adenocarcinoma)

Stop Tx as per protocol:
 19 patients
 MRD(-) -> MRD(+) (3)

No. at risk:		Time (months)					
		0	12	24	36	48	60
OS	50	48	37	21	7	0	0
PFS	50	48	36	21	6	0	0
EFS	50	46	31	17	4	0	0

OASIS: Patients' outcome

- mFU = 14 months (range, 5 to 19)
- One patient progressed (not *TP53* mutated nor 17p deleted)
- 14 patients remain in CR and under treatment


- PFS at one year is 93.3% (95% CI, 81.5- 100%)

- OS at one and two years is 100%


Le Gouill, EHA 2020; Blood 2021

Wang, ASH 2021, #2416 : Acala/Venetoclax/Ritux



PFS



OS



LOXO-305 Treatment Duration in Mantle Cell Lymphoma




Wang, ASH 2021, #381

Eyre, ASH 2021, #2422: Phase 3 against BTKi

Wang, ASH 2020

Relapsed or Refractory MCL




Parsaclisib (CITADEL-205)



CAR T-cells in MCL

Survival rates

- The medians for DOR, PFS, and OS were not reached after a median follow-up of 17.5 months




Wang, ASH 2020


Y. Wang, ASH 2021, #744 : Real life experience

Time on treatment and response

Aggressive NHL




Indolent NHL



European MCL Network

Potential future therapeutic algorithm ?





European MCL network * Paris 2021

Acknowledgements

